People fighting colorectal cancer can now continue to use an anti-cancer drug with other forms of chemotherapy, even if the drug’s first use didn’t halt their cancer.
Avastin, a drug from Roche (PINK:RHHBY), had already been approved for use with chemotherapy to treat colorectal cancer. On Wednesday, the U.S. Food & Drug Administration approved its repeated use with alternative forms of chemotherapy if the earlier treatment hadn’t mitigated the cancer, The Financial Express noted.
Used to treat brain, lung, kidney and colorectal cancers, Avastin is designed to block the production of a protein required for cancerous tumors to grow. In 2011, it generated global sales of $5.5 billion.
The FDA based its decision on clinical research indicating that additional rounds of Avastin combined with new chemotherapy increased survival rates among colorectal cancer patients, compared to those who took new chemotherapy treatments alone.
Shares of Roche rose fractionally in over-the-counter trading on Thursday.